title: Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
abstract: Equilibrium striatal: cerebellar 11C-raclopride (RAC) uptake ratios reflect the density of striatal dopamine D2 binding sites. Using positron emission tomographic scanning we have measured striatal RAC uptake in 6 untreated patients with Parkinson's disease (PD), 5 chronically treated patients with PD and a fluctuating response to L-dopa, 10 patients with striatonigral degeneration (SND), and 9 patients with progressive supranuclear palsy (PSP). Regional cerebral blood flow was determined also, with C15O2. Mean striatal: cerebellar RAC uptake was not significantly different from normal in untreated patients with PD, though 2 of these 6 patients showed significantly increased putamen tracer binding. Mean caudate and putamen: cerebellar RAC uptake ratios of the group with PD and a fluctuating response to L-dopa were significantly reduced by 30% and 18%, respectively. The patients with SND had lesser, but significant, 10% and 11% decreases in mean caudate and putamen: cerebellar RAC uptake ratios, respectively, whereas patients with PSP showed 24% and 9% reductions in caudate and putamen: cerebellar RAC binding. Striatal and frontal blood flow were significantly reduced in patients with PSP, but not in patients with PD or SND. In conclusion, striatal D2 binding potential is normal or raised in untreated patients with PD, but reduced in patients with PD and a fluctuating response to L-dopa. Patients with SND and PSP show a decrease in striatal RAC binding, but to a lesser extent than patients with PD and a fluctuating response to treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: MRC Cyclotron Unit, Hammersmith Hospital, London, UK.
authors.forename: D J
authors.initials: DJ
authors.lastname: Brooks
authors.forename: V
authors.initials: V
authors.lastname: Ibanez
authors.forename: G V
authors.initials: GV
authors.lastname: Sawle
authors.forename: E D
authors.initials: ED
authors.lastname: Playford
authors.forename: N
authors.initials: N
authors.lastname: Quinn
authors.forename: C J
authors.initials: CJ
authors.lastname: Mathias
authors.forename: A J
authors.initials: AJ
authors.lastname: Lees
authors.forename: C D
authors.initials: CD
authors.lastname: Marsden
authors.forename: R
authors.initials: R
authors.lastname: Bannister
authors.forename: R S
authors.initials: RS
authors.lastname: Frackowiak
mesh_terms: D000328:Adult; D000368:Aged; D002421:Caudate Nucleus / Q000000981:diagnostic imaging / Q000378:metabolism; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D009410:Nerve Degeneration; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism*; D011699:Putamen / Q000000981:diagnostic imaging / Q000378:metabolism; D020891:Raclopride; D011954:Receptors, Dopamine / Q000032:analysis* / Q000187:drug effects; D012457:Salicylamides / Q000493:pharmacokinetics; D013378:Substantia Nigra / Q000000981:diagnostic imaging / Q000378:metabolism*; D013494:Supranuclear Palsy, Progressive / Q000000981:diagnostic imaging / Q000378:metabolism*; D014055:Tomography, Emission-Computed
chemical_list: D011954:Receptors, Dopamine; D012457:Salicylamides; D020891:Raclopride; D007980:Levodopa